These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 34027585)
1. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer. Chopra A; Zenati M; Hogg ME; Zeh HJ; Bartlett DL; Bahary N; Zureikat AH; Beane JD Ann Surg Oncol; 2021 Nov; 28(12):7759-7769. PubMed ID: 34027585 [TBL] [Abstract][Full Text] [Related]
2. Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis. Daamen LA; van Goor IWJM; Schouten TJ; Dorland G; van Roessel SR; Besselink MG; Bonsing BA; Bosscha K; Brosens LAA; Busch OR; van Dam RM; Fariña Sarasqueta A; Festen S; Groot Koerkamp B; van der Harst E; de Hingh IHJT; Intven MPW; Kazemier G; de Meijer VE; Nieuwenhuijs VB; Raicu GM; Roos D; Schreinemakers JMJ; Stommel MWJ; van Velthuysen MF; Verheij J; Verkooijen HM; van Santvoort HC; Molenaar IQ; Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):708-716. PubMed ID: 33323293 [TBL] [Abstract][Full Text] [Related]
3. Clinical impact of additional therapy for residual pancreatic cancer. Yamada S; Sonohara F; Tashiro M; Murotani K; Takami H; Hayashi M; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujii T; Kodera Y Surg Today; 2020 May; 50(5):440-448. PubMed ID: 31650262 [TBL] [Abstract][Full Text] [Related]
4. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium. Kelly KN; Macedo FI; Seaton M; Wilson G; Hammill C; Martin RC; Maduekwe UN; Kim HJ; Maithel SK; Abbott DE; Ahmad SA; Kooby DA; Merchant NB; Datta J Ann Surg Oncol; 2022 Sep; 29(9):6004-6012. PubMed ID: 35511392 [TBL] [Abstract][Full Text] [Related]
5. R Status is a Relevant Prognostic Factor for Recurrence and Survival After Pancreatic Head Resection for Ductal Adenocarcinoma. Crippa S; Giannone F; Schiavo Lena M; Belfiori G; Partelli S; Tamburrino D; Delpini R; Pagnanelli M; Pecorelli N; Balzano G; Doglioni C; Falconi M Ann Surg Oncol; 2021 Aug; 28(8):4602-4612. PubMed ID: 33393031 [TBL] [Abstract][Full Text] [Related]
6. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment. Leonhardt CS; Pils D; Qadan M; Jomrich G; Assawasirisin C; Klaiber U; Sahora K; Warshaw AL; Ferrone CR; Schindl M; Lillemoe KD; Strobel O; Fernández-Del Castillo C; Hank T Ann Surg; 2024 Feb; 279(2):314-322. PubMed ID: 37042245 [TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic review and meta-analysis. Leonhardt CS; Hank T; Pils D; Gustorff C; Sahora K; Schindl M; Verbeke CS; Strobel O; Klaiber U Int J Surg; 2024 Jan; 110(1):453-463. PubMed ID: 38315795 [TBL] [Abstract][Full Text] [Related]
8. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Tummers WS; Groen JV; Sibinga Mulder BG; Farina-Sarasqueta A; Morreau J; Putter H; van de Velde CJ; Vahrmeijer AL; Bonsing BA; Mieog JS; Swijnenburg RJ Br J Surg; 2019 Jul; 106(8):1055-1065. PubMed ID: 30883699 [TBL] [Abstract][Full Text] [Related]
9. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Ghaneh P; Kleeff J; Halloran CM; Raraty M; Jackson R; Melling J; Jones O; Palmer DH; Cox TF; Smith CJ; O'Reilly DA; Izbicki JR; Scarfe AG; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Padbury R; Shannon J; Dervenis C; Glimelius B; Deakin M; Anthoney A; Lerch MM; Mayerle J; Oláh A; Rawcliffe CL; Campbell F; Strobel O; Büchler MW; Neoptolemos JP; Ann Surg; 2019 Mar; 269(3):520-529. PubMed ID: 29068800 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study. Kamarajah SK; White SA; Naffouje SA; Salti GI; Dahdaleh F Ann Surg Oncol; 2021 Oct; 28(11):6790-6802. PubMed ID: 33786676 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy. Hammad AY; Hodges JC; AlMasri S; Paniccia A; Lee KK; Bahary N; Singhi AD; Ellsworth SG; Aldakkak M; Evans DB; Tsai S; Zureikat A JAMA Surg; 2023 Jan; 158(1):55-62. PubMed ID: 36416848 [TBL] [Abstract][Full Text] [Related]
12. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Konstantinidis IT; Warshaw AL; Allen JN; Blaszkowsky LS; Castillo CF; Deshpande V; Hong TS; Kwak EL; Lauwers GY; Ryan DP; Wargo JA; Lillemoe KD; Ferrone CR Ann Surg; 2013 Apr; 257(4):731-6. PubMed ID: 22968073 [TBL] [Abstract][Full Text] [Related]
13. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy. Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659 [TBL] [Abstract][Full Text] [Related]
14. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation. Sekigami Y; Michelakos T; Fernandez-Del Castillo C; Kontos F; Qadan M; Wo JY; Harrison J; Deshpande V; Catalano O; Lillemoe KD; Hong TS; Ferrone CR Ann Surg Oncol; 2021 Aug; 28(8):4592-4601. PubMed ID: 33393047 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study. Delpero JR; Jeune F; Bachellier P; Regenet N; Le Treut YP; Paye F; Carrere N; Sauvanet A; Adham M; Autret A; Poizat F; Turrini O; Boher JM Ann Surg; 2017 Nov; 266(5):787-796. PubMed ID: 28953554 [TBL] [Abstract][Full Text] [Related]
16. Effect of resection margin status on recurrence pattern and survival in distal pancreatectomy for left-sided pancreatic ductal adenocarcinoma. Kwon J; Lee SR; Park SY; Lee JH; Song KB; Hwang DW; Shin JH; Kim SC J Hepatobiliary Pancreat Sci; 2023 May; 30(5):633-643. PubMed ID: 36380718 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of the circumferential resection margin and its definitions in esophageal cancer patients after neoadjuvant chemoradiotherapy. Depypere L; Moons J; Lerut T; De Hertogh G; Peters C; Sagaert X; Coosemans W; Van Veer H; Nafteux P Dis Esophagus; 2018 Feb; 31(2):. PubMed ID: 29036407 [TBL] [Abstract][Full Text] [Related]
18. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review. Datta J; Willobee BA; Ryon EL; Shah MM; Drebin JA; Kooby DA; Merchant NB JAMA Surg; 2021 May; 156(5):489-495. PubMed ID: 33533898 [TBL] [Abstract][Full Text] [Related]
19. The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Nitta T; Nakamura T; Mitsuhashi T; Asano T; Okamura K; Tsuchikawa T; Tamoto E; Murakami S; Noji T; Kurashima Y; Ebihara Y; Nakanishi Y; Shichinohe T; Hirano S Surg Today; 2017 Apr; 47(4):490-497. PubMed ID: 27677294 [TBL] [Abstract][Full Text] [Related]
20. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. Lee SH; Hwang DW; Yoo C; Kim KP; Kang S; Jeong JH; Oh D; Song TJ; Lee SS; Park DH; Seo DW; Park JH; Song KB; Lee JH; Lee W; Park Y; Kwak BJ; Chang HM; Ryoo BY; Kim SC Cancer Res Treat; 2023 Jul; 55(3):956-968. PubMed ID: 36915253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]